BLU-5937
Sponsors
Bellus Health Inc., Bellus Health Inc. - a GSK company, GlaxoSmithKline
Conditions
Atopic DermatitisChronic PruritusChronic Refractory CoughCoughHealthyIncluding Unexplained Chronic CoughRefractory Chronic Cough
Phase 1
BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect
CompletedNCT03638180
Start: 2018-07-09End: 2018-10-25Updated: 2018-11-09
Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects
CompletedNCT06179537
Start: 2021-08-06End: 2021-11-21Updated: 2023-12-22
Phase 2
A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
TerminatedNCT03979638
Start: 2019-07-10End: 2020-04-23Updated: 2021-08-03
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
CompletedNCT04678206
Start: 2020-12-07End: 2021-11-02Updated: 2021-12-13
A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis
CompletedNCT04693195
Start: 2020-12-09End: 2021-10-12Updated: 2022-10-17
Phase 3
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
CompletedNCT05599191
Start: 2022-10-25End: 2026-06-18Updated: 2026-07-14
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Active, not recruitingNCT05600777
Start: 2022-12-05End: 2027-03-17Updated: 2026-07-14
A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2)
Active, not recruitingCTIS2024-513462-19-00
Start: 2023-03-30Target: 257Updated: 2025-11-12
A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1)
Active, not recruitingCTIS2024-513460-26-00
Start: 2023-03-29Target: 275Updated: 2025-12-04
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
RecruitingNCT07650084
Start: 2025-11-21End: 2028-06-02Target: 75Updated: 2026-06-16